|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Nicardipine#Overdosage]] |
| {{Nicardipine}}
| |
| {{CMG}}; {{AE}}:{{AK}}
| |
| | |
| '''''For patient information about Nicardipine, click [[Nicardipine (patient information)|here]].'''''
| |
| | |
| ==OVERDOSAGE==
| |
| | |
| Three overdosages with CARDENE or CARDENE SR have been reported. Two occurred in adults, 1 of whom ingested 600 mg of CARDENE and the other 2160 mg of CARDENE SR. Symptoms included marked hypotension,[[ bradycardia]], [[palpitations]], flushing, [[drowsiness]], confusion, and slurred speech. All symptoms resolved without sequelae. The third over-dosage occurred in a 1-year-old child who ingested half of the powder in a 30-mg CARDENE capsule. The child remained asymptomatic.
| |
| | |
| Based on results obtained in laboratory animals, overdosage may cause systemic [[hypotension]], bradycardia (following initial tachycardia) and progressive atrioventricular conduction block. Reversible hepatic function abnormalities and sporadic focal hepatic necrosis were noted in some animal species receiving very large doses of nicardipine.
| |
| | |
| For treatment of overdose standard measures (for example, evacuation of gastric contents, elevation of extremities, attention to circulating fluid volume, and urine output) including monitoring of cardiac and respiratory functions should be implemented. The patient should be positioned so as to avoid cerebral anoxia. Frequent blood pressure determinations are essential. Vasopressors are clinically indicated for patients exhibiting profound hypotension. Intravenous [[calcium gluconate]] may help reverse the effects of calcium entry blockade.<ref> {{cite web | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce141ca0-d734-11df-8537-0002a5d5c51b | title = CARDENE SR (nicardipine hydrochloride) capsule, extended release [EKR Therapeutics] | accessdate =}}</ref>
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |